

Heterologous Membrane Protein Production System

(OTT ID 1006)

**Inventor: M.L.P. Collins, Ph.D., Professor Emeritus, Department of
Biology, University of Wisconsin-Milwaukee**

**For further information please
contact:**

**Jessica M. Silvaggi, Ph.D.
Senior Licensing Manager
UWM Research Foundation
1440 East North Ave.
Milwaukee, WI 53202
Tel: 414-906-4654
jessica@uwmrf.org**

- **Importance**
 - Membrane proteins account for 30-50% of the most promising pharmaceutical targets
- **Problems**
 - Membrane proteins are difficult to synthesize in large quantities
 - Current systems produce small amounts that are often misfolded, inactive, or toxic to host cells
- **Solution**
 - The bacterium *Rhodospirillum rubrum* forms an intracytoplasmic membrane (ICM) in response to membrane protein synthesis
 - The ICM is non-essential for growth and can incorporate foreign and over-expressed membrane proteins without disrupting normal cellular function
 - Gene expression is regulated in a non-toxic and inexpensive fashion by adjusting oxygen levels
 - Active and correctly folded membrane proteins can be expressed with a high yield

Applications:

- Therapeutic protein production
- Vaccine development
- Antibody production
- Production of high value proteins
- Commercial Protein Expression Kits
 - Crystallographic preparations
 - NMR preparations
 - Ligand/inhibitor assays
 - High through-put screening assay materials
 - Basic research use


Market:

- Global Industry Analysts has predicted that the global market for protein drugs is forecast to reach \$158 billion by 2015.
- The life science tools market has continued to show steady growth over the last few years and is currently valued at more than \$42 billion (BCC Research 2011)
- The market is predicted to grow to \$81 billion by 2016. Protein research-related tools are projected to rise to \$9.1 billion in 2016.

- Issued U.S. Patent 6,680,179
- Issued U.S. Patent 6,951,741
- Issued U.S. Patent 8,481,287
- This technology is available for licensing
- We are looking for partners to aid in finalizing the development of the expression kit into a marketable product for both scientific research and industrial use.
- The kit has been further developed to work using electrocompetent bacterial cells for electroporation of the vector containing the gene of interest.
- We are also looking for partners interested in utilizing the expression system internally for protein production for pharmaceutical products (i.e. vaccines, therapeutics, etc.)

- The kit is has been transferred through material transfer agreements to several universities and companies
- Type of proteins being tested or already tested:
 - Efflux transporter protein (*P. aeruginosa*)
 - Chemokine proteins for testing structure-function relationships
 - Inner mitochondrial membrane transport proteins (human)
 - Rice protein involved in low temperature signaling
 - Magnetosome proteins
 - Human ETF-QO
 - *M. tuberculosis* drug target candidates
 - Integral membrane proteins
 - Anion channel proteins

Intracytoplasmic Membrane (ICM) formation



- Mutants lacking the structural proteins of the photochemical apparatus do not form ICM but retain the capacity to do so when a native or foreign membrane protein is synthesized


Host: *R. rubrum* H2 (*puhA*, *pufBALM* mutant)

Vector: pPUCTerm

Rhodobacter capsulatus *puc* promoter regulated by oxygen





Production of MscL with reduced oxygen



MscL = 14 kDa *Pseudomonas* transport protein with 2 transmembrane domains
 aer = aerobic conditions
 ind = reduced oxygen conditions


Method for Harvesting from ICM







- MscL is enriched in the intracytoplasmic membrane fraction compared to the cell envelope

Expression vector control



Method for Protein Production





R. rubrum vs. *E. coli* expression


R. rubrum:

- 23.4 mg/L
- 5.6 mg/g cell paste

E. coli C43 (DE3):

- No detectable MscL recovered using same protein recovery system
- MscL appears to be in inclusion bodies

Direct comparison in *E. coli*




- Supn is 230,000 x g supernatant fraction
- CMF is crude membrane fraction (230,000 x g pellet)
- SMP is DDM solubilized membrane protein

Streptomyces lividans

Pseudomonas aeruginosa

KcsA

CycB



KcsA in *R. rubrum*

- 13.7 – 14.4 mg/L
- 2.19-2.55 mg/g cell paste
- Purified to homogeneity

KcsA in *E. coli* C41

- 4.5 mg/L
- 75% pure
- Ron Viola, personal communication

<u>Protein</u>	<u>mg/L culture</u>	<u>mg/g cell paste</u>	<u>mg/mg crude membrane protein</u>
MscL	22.8 – 23.4	5.53 – 5.60	0.81 – 0.106
KcsA	13.7 – 14.4	2.19 – 2.55	0.042 – 0.081
CycB	6.57 – 7.36	1.12 – 1.21	0.038 – 0.065

- CycB difference spectrum and heme peroxidase activity
- Purified MscL and KcsA are present as oligomers

- This protein expression kit allows for the expression of foreign membrane proteins where other expression systems may fail
- Potential for efficient, large-scale production of proteins for multiple uses such as vaccines, therapeutics, enzyme therapies and basic research
- Purification of the membrane protein is simple
- Expression of the system is simple and inexpensive using low oxygen levels
- The bacterium *R. rubrum* is easy to work with and non-pathogenic

- Needs a multiple cloning site in vector; currently only 2 sites
- Carry out further side by side expression testing with *E. coli* to evaluate
- Optimize competent cells to be use with kit

Heterologous Membrane Protein Production System

(OTT ID# 1006)

Inventor: M.L.P. Collins, Ph.D.

For further information please contact:

Jessica M. Silvaggi, Ph.D.
Senior Licensing Manager
UWM Research Foundation
1440 East North Ave.
Milwaukee, WI 53202
Tel: 414-906-4654
jessica@uwmrf.org